Viridian Therapeutics, Inc. (VRDN) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Join SI Premium – FREE
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.00), in-line with the analyst estimate of ($1.00). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50.92 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- Edgewell stock surges on report of rejected takeover bid
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
